ACCLAIM CTA

a phase3, randomized, double blind, placebo-controlled trial of lepodisiran to investigate the effect on coronary plaque in adults with elevated Lp(a) who have established atherosclerotic cardiovascular disease or are at risk for a first cardiovascular event